Enterolactone Inhibits Insulin-Like Growth Factor-1 Receptor Signaling in Human Prostatic Carcinoma PC-3 Cells
- 1 April 2009
- journal article
- Published by Elsevier BV in Journal of Nutrition
- Vol. 139 (4), 653-659
- https://doi.org/10.3945/jn.108.101832
Abstract
Enterolactone, a major metabolite of plant-based lignans, has been shown to inhibit prostate cancer growth and development, but the mechanistic basis for its anticancer activity remains largely unknown. Activation of insulin-like growth factor-1 (IGF-1) receptor (IGF-1R) signaling is critical for prostate cancer cell growth and progression. This study examined whether the growth inhibitory effect of enterolactone was related to changes in the IGF-1/IGF-1R system in PC-3 prostate cancer cells. At nutritionally relevant concentrations (20–60 μmol/L), enterolactone inhibited IGF-1–induced activation of IGF-1R and its downstream AKT and mitogen-activated protein kinase/extracellular-signal regulated kinase signaling pathways. Inhibition of AKT by enterolactone resulted in decreased phosphorylation of its downstream targets, including p70S6K1 and glycogen synthase kinase-3 β. Enterolactone also inhibited cyclin D1 expression. As a result, enterolactone inhibited proliferation and migration of PC-3 cells. Knockdown of IGF-1R by plasmids with siRNA (si) against IGF-1R mRNA resulted in inhibition of proliferation of PC-3 cells and cell numbers did not differ when the si-IGF-1R groups (cells transfected with plasmids containing siRNA against IGF-1R mRNA) were treated or untreated with enterolactone. These results suggest that enterolactone suppresses proliferation and migration of prostate cancer cells, at least partially, through inhibition of IGF-1/IGF-1R signaling. The finding of this study provides new insights into the molecular mechanisms that enterolactone exerts against prostate cancer.Keywords
This publication has 47 references indexed in Scilit:
- Flaxseed Supplementation (Not Dietary Fat Restriction) Reduces Prostate Cancer Proliferation Rates in Men PresurgeryCancer Epidemiology, Biomarkers & Prevention, 2008
- Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.JNCI Journal of the National Cancer Institute, 2002
- Effect of mammalian lignans on the growth of prostate cancer cell lines.2002
- In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).2001
- Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic featuresUrology, 2001
- Insulin-like growth factors and prostate cancer.Epidemiologic Reviews, 2001
- Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective StudyJNCI Journal of the National Cancer Institute, 2000
- Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic miceProceedings of the National Academy of Sciences of the United States of America, 2000
- Insulin-like growth factor I receptor signalling in prostate cancer cells.Growth Hormone & IGF Research, 2000
- Oxidative Metabolism of the Mammalian Lignans Enterolactone and Enterodiol by Rat, Pig, and Human Liver MicrosomesJournal of Agricultural and Food Chemistry, 1999